Alpine Immune Sciences Inc ALPN:NASDAQ

Last Price$8.01NASDAQ Closing Price as of 4:00PM ET 5/19/22

Today's Change+0.06(0.75%)
Bid (Size)$8.00 (5)
Ask (Size)$8.04 (1)
Day Low / High$7.80 - 8.14
Volume73.7 K
 

View Biotechnology IndustryPeer Comparison as of 05/19/2022

 

Alpine Immune Sciences Inc ( NASDAQ )

Price: $8.01
Change: +0.06 (0.75%)
Volume: 73.7 K
4:00PM ET 5/19/2022
 
 

Voyager Therapeutics Inc ( NASDAQ )

Price: $6.38
Change: +0.08 (1.27%)
Volume: 288.1 K
4:00PM ET 5/19/2022
 
 

bluebird bio Inc ( NASDAQ )

Price: $3.35
Change: +0.02 (0.60%)
Volume: 2.0 M
4:00PM ET 5/19/2022
 
 

Jounce Therapeutics Inc ( NASDAQ )

Price: $4.52
Change: -0.08 (1.74%)
Volume: 364.4 K
4:00PM ET 5/19/2022
 
 

VistaGen Therapeutics Inc ( NASDAQ )

Price: $1.11
Change: -0.03 (2.63%)
Volume: 699.0 K
4:00PM ET 5/19/2022
 

Read more news Recent News

-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Posts Q1 Revenue $13.6M
4:27PM ET 5/12/2022 MT Newswires

...

Alpine Immune Q4 Loss Widens Amid Lower Revenue; Sees Enough Funds Through 2024
5:11PM ET 3/17/2022 MT Newswires

Alpine Immune Sciences (ALPN) on Thursday widened its net loss to $0.52 per share in Q4 from $0.27 per share a year earlier. Analysts polled by Capital IQ...

-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Posts Q4 Revenue $4.5M
4:05PM ET 3/17/2022 MT Newswires

...

Alpine Says FDA Places Partial Clinical Hold on Study of Davoceticept Drug Cocktail in Advanced Malignancies
9:48AM ET 3/07/2022 MT Newswires

Alpine Immune Sciences (ALPN) said Monday the US Food and Drug Administration placed its clinical study of davoceticept in combination with pembrolizumab...

Company Profile

Business DescriptionAlpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA. View company web site for more details
Address188 East Blaine Street
Seattle, Washington 98102
Phone+1.206.788.4545
Number of Employees48
Recent SEC Filing05/12/202210-Q
Executive Chairman & Chief Executive OfficerMitchell H. Gold
President & Head-Research & DevelopmentStanford L. Peng
Finance DirectorThaedra Thullberry
Chief Financial Officer, Secretary & Senior VPJames Paul Rickey

Company Highlights

Price Open$7.90
Previous Close$7.95
52 Week Range$6.00 - 15.14
Market Capitalization$242.9 M
Shares Outstanding30.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.97
Beta vs. S&P 500N/A
Revenue$705.0 K
Net Profit Margin-214.70%
Return on Equity-59.07%

Analyst Ratings as of 10/14/2021

Buy
4
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset